文献速递细菌感染、耐药与抗菌药物医院感染防控

高碳青霉烯耐药革兰阴性菌流行环境下脓毒症患者经验性使用多黏菌素的粗死亡率:一项队列的回顾性分析

Crude Mortality Associated With the Empirical Use of Polymyxins in Septic Patients in a Setting of High Prevalence of Carbapenem-Resistant Gram-negative Bacteria: Retrospective Analysis of a Cohort.
PubMed 文献 · Clin Infect Dis · 2023-01-01

该回顾性队列研究在巴西一家三级学术医院纳入203例疑似脓毒症患者,评估经验性使用多黏菌素对碳青霉烯耐药革兰阴性菌(CR-GNB)感染患者死亡率的影响。结果显示,经验性使用多黏菌素与14天粗死亡率降低无关(aOR 0.71,95%CI 0.29-1.71,P=0.44)。

要点

  • 203例疑似脓毒症患者中,140例(69%)接受了多黏菌素单药或联合治疗。
  • 14天总粗死亡率为30%。
  • 经验性使用多黏菌素与14天粗死亡率降低无关(aOR 0.71,95%CI 0.29-1.71,P=0.44)。

核心结论

  • 在高CR-GNB流行环境中,对脓毒症患者经验性使用多黏菌素与14天粗死亡率降低无关(aOR 0.71,95%CI 0.29-1.71,P=0.44)。

研究设计与样本

  • 回顾性队列研究;在巴西一家三级学术医院开展,时间为2018年1月至2020年1月,即2019年冠状病毒病(COVID-19)前时期;共纳入203例疑似脓毒症患者;采用logistic回归模型评估与14天粗死亡率相关的危险因素,并使用多黏菌素倾向性评分控制偏倚。

主要发现

  • 203例患者中70例(34%)从任一临床培养中分离出至少1种多重耐药菌。
  • 203例患者中140例(69%)接受多黏菌素单药或联合治疗。
  • 14天总粗死亡率为30%。
  • 14天粗死亡率与年龄(aOR 1.03;95%CI 1.01-1.05;P=0.01)、SOFA评分值(aOR 1.2;95%CI 1.09-1.32;P<0.001)、CR-GNB感染(aOR 3.94;95%CI 1.53-10.14;P=0.005)以及疑似脓毒症至抗生素给药时间(aOR 0.73;95%CI 0.65-0.83;P<0.001)相关。
  • 经验性使用多黏菌素与14天粗死亡率降低无关(aOR 0.71;95%CI 0.29-1.71;P=0.44)。

关键数值与推荐

  • 首剂抗生素从「脓毒症抗生素套件」中开具,该套件包含多黏菌素在内的多种药物,无预先审批政策。
  • 14天总粗死亡率为30%。
  • 经验性使用多黏菌素与14天粗死亡率降低无关(aOR 0.71;95%CI 0.29-1.71;P=0.44)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Our aim in this retrospective cohort study was to assess the impact on mortality of the empirical use of polymyxin as therapy for carbapenem-resistant gram-negative bacteria (CR-GNB) in septic patients. The study was performed at a tertiary academic hospital in Brazil, from January 2018 to January 2020, the pre-coronavirus disease 2019 period. METHODS: We included 203 patients with suspected sepsis. The first doses of antibiotics were prescribed from a "sepsis antibiotic kit", which contained a selection of drugs, including polymyxin, with no preapproval policy. We developed a logistic regression model to assess risk factors associated with 14-day crude mortality. Propensity score for polymyxin was used to control biases. RESULTS: Seventy (34%) of 203 patients had infections with at least 1 multidrug-resistant organism isolated from any clinical culture. Polymyxins in monotherapy or in combination therapy were prescribed to 140 of the 203 (69%) patients. The overall 14-day mortality rate was 30%. The 14-day crude mortality was associated with age (adjusted odds ratio [aOR], 1.03; 95% confidence interval [CI], 1.01-1.05; P = .01), SOFA (sepsis-related organ failure assessment) score value (aOR, 1.2; 95% CI, 1.09-1.32; P < .001), CR-GNB infection (aOR, 3.94; 95% CI, 1.53-10.14; P = .005), and time between suspected sepsis and antibiotic administration (aOR, 0.73; 95% CI, .65-.83; P < .001). The empirical use of polymyxins was not associated with decreased crude mortality (aOR, 0.71; 95% CI, .29-1.71; P = .44). CONCLUSIONS: Empirical use of polymyxin for septic patients in a setting with high CR-GNB prevalence was not associated with decreased crude mortality.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Bezerra CLPAM, Dos Santos EL, Oliveira MS, et al. Crude Mortality Associated With the Empirical Use of Polymyxins in Septic Patients in a Setting of High Prevalence of Carbapenem-Resistant Gram-negative Bacteria: Retrospective Analysis of a Cohort. Clin Infect Dis. 2023. PMID: 37406048. doi:10.1093/cid/ciad272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。